Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study

Table 1 Subject characteristics at baseline

	Anagliptin	Linagliptin	P-value
Age (yr)	63.5 (12.9)	62.7 (11.9)	0.63
Men/women	74/43	75/42	0.89
Height (cm)	162.1 (10.4)	162.5 (9.1)	0.77
Weight (kg)	64.4 (16.1)	66.1 (14.7)	0.39
BMI (kg/m2)	24.3 (4.7)	24.9 (4.3)	0.23
Duration of diabetes (yr)	11.9 (8.6)	10.5 (8.5)	0.21
History of CVD (yes/no)	36/81	32/85	0.56
Smoking habit (yes/no)	44/73	46/71	0.79
Drinking habit (yes/no)	65/52	62/55	0.75
SBP (mmHg)	130.4 (18.4)	128.5 (18.7)	0.43
DBP (mmHg)	72.9 (14)	72.9 (11.4)	0.99
AST (U/L)	21.9 (9.3)	29.8 (26.7)	0.029
ALT (U/L)	24.9 (15)	33.1 (35.1)	0.069
Cr (mg/dL)	0.71 (0.19)	0.79 (0.32)	0.03
PG (mmol/L)	10.71 (4.49)	12.06 (5.25)	0.036
HbA1c (mmol/L)	11.1 (2.8)	12 (3.3)	0.053
T-C (mmol/L)	5.3 (0.88)	5.48 (1.02)	0.17
TG (mmol/L)	1.63 (1.17)	2.07 (1.5)	0.009
HDL-C (mmol/L)	1.36 (0.34)	1.33 (0.37)	0.55
LDL-C (mmol/L)	3.19 (0.8)	3.19 (0.88)	0.95
UACR (mg/gCr)	50.60 (78.4)	47.6 (92)	0.65

BMI: Body mass index; CVD: Cardiovascular disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; AST: Aspartate transaminase; ALT: Alanine aminotransferase; Cr: Creatinine; PG: Plasma glucose; HbA1c: Hemoglobin A1c; T-C: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; UACR: Urinary albumin creatinine ratio.